Neuro-Oncology Anywhere: Remote Monitoring and Metformin for Cognitive Decline in Cranial Radiation Patients

Phase 2, randomised, open-label trial of liquid metformin (Aspargo Labs) in No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity (2 arms), sponsored by Mayo Clinic. Primary endpoint: Compliance of patients who complete the testing schedule for the cognitive assessments at 6 months. Started May 2024; status: active, not recruiting.